Evidence map›Paper›PMID 42502392›Full record

ArticleiScience2026

Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma.

Jia-Jye Lee, Peirong Hu, Kun Luo, Jinling Wang, Emily Neil, Dongju Park, Robert Pinard, Yazeed Sawalha, Nathan Denlinger, Evandro Bezerra and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jia-Jye LeeLentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.
Peirong HuLentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.
Kun LuoLentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.
Jinling WangMiltenyi Biotec, Inc., Waltham, MA, USA.
Emily NeilMiltenyi Biotec, Inc., Waltham, MA, USA.
Dongju ParkMiltenyi Biotec, Inc., Waltham, MA, USA.
Robert PinardMiltenyi Biotec, Inc., Waltham, MA, USA.
Yazeed SawalhaThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Nathan DenlingerThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Evandro BezerraThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Pradyot DashLentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.
Dina SchneiderLentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.
Ashley KrullThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Lynn OdonnellThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Lapo AlinariThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Wing Keung ChanThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Dan JonesThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Rimas J OrentasLentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.
Marcos de LimaThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Sumithira VasuThe James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD19-directed chimeric antigen receptor (CAR)-engineered T cells have transformed cellular therapy for hematologic malignancies but have also raised concerns about secondary malignancies. A spatial profiling method was used to analyze the tumor microenvironment and define native and CAR T cell association with a pleomorphic sarcoma arising 12 months post-CAR T therapy for B cell lymphoma. Although CAR T sequences were absent in the secondary tumor, our approach enabled profiling of the stroma, tumor, and infiltrating T cells. Spatial analysis incorporated proteomics via serial antibody staining and transcriptomics using RNA hybridization on an automated MACSima imaging cyclic staining (MICS) system, which allows for

Indexed as

CAR-T cellimmunotherapysecondary malignancyspatial profiling

Identifiers

PMID42502392
PMCPMC13400778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.